Tech Company Financing Transactions
Belharra Therapeutics Funding Round
Genentech and Versant Ventures participated in a $130 million Series A funding round for Belharra Therapeutics. The round was announced on 1/4/2023.
Transaction Overview
Company Name
Announced On
1/4/2023
Transaction Type
Venture Equity
Amount
$130,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate growth and expand operations.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3985 Sorrento Valley Blvd
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
Belharra Therapeutics, Inc.?is a privately held?drug discovery company whose novel?photoaffinity-based chemoproteomics platform?is disrupting the drug discovery paradigm. Guided by a diverse team of?biotech trailblazers, Belharra's proprietary noncovalent?drug discovery engine is uniquely?capable of identifying?novel starting points for?transformative medicines?to address?previously impossible-to-treat diseases and conditions.?
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeff Jonker
Co-Founder
Christopher Parker
Browse more venture capital transactions:
Prev: 1/4/2023: Product Science venture capital transaction
Next: 1/4/2023: Snaptrude venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs